- TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
-
This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C1, C2, Z1, Z2, Q, J, R1, and R3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.
- -
-
Page/Page column 55; 56
(2012/06/01)
-
- METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
-
This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.
- -
-
-
- 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: Orally bioavailable compounds
-
Structure-activity relationships and efforts to optimize the pharmacokinetic profile of a class of 2-arylimino-5,6-dihydro-4H-1,3-thiazines as cannabinoid receptor agonists are described. Among the compounds examined, compound 14 showed potent affinity and high selectivity for CB2, and compound 23 showed potent affinities against CB1 and CB2. These compounds displayed oral bioavailability.
- Kai, Hiroyuki,Morioka, Yasuhide,Tomida, Minoru,Takahashi, Tadashi,Hattori, Maki,Hanasaki, Kohji,Koike, Katsumi,Chiba, Hiroki,Shinohara, Shunji,Kanemasa, Toshiyuki,Iwamoto, Yuka,Takahashi, Kohji,Yamaguchi, Yoshitaka,Baba, Takahiko,Yoshikawa, Takayoshi,Takenaka, Hideyuki
-
p. 3925 - 3929
(2008/02/11)
-